Brian Markison is a seasoned executive with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. He currently serves as the Non-Executive Chairman of Lantheus Medical Imaging as well as a Healthcare Industry Executive for Avista and serves on the Board of Directors of National Spine and Pain Centers, LLC and the College of New Jersey. Mr. Markison is currently the Chief Executive Officer and a Director of Osmotica Holdings, SCSp, after serving as Executive Chairman of one of its predecessor companies, Vertical/Trigen Holdings, LLC. He previously held the position of President and Chief Executive Officer and member of the Board of Directors of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company in dermatology. Before leading Fougera, Mr. Markison was Chairman and Chief Executive Officer of King Pharmaceuticals, which he joined as Chief Operating Officer in March 2004, and was promoted to President and Chief Executive Officer later that year. Mr. Markison has held various senior leadership positions at Bristol-Meyers Squibb.
Jeffrey Berkowitz, J.D. is a former Executive Vice President of UnitedHealth Group/Optum where he led Optum’s International division while also driving key strategic initiatives within Optum’s pharmacy benefits management division. Prior to UnitedHealth Group/Optum he was Executive Vice President and President of Pharma and Global Market Access at the Walgreens Boots Alliance, Inc. Previously, he served as an executive at Merck and Schering-Plough and as a lawyer with Proskaur, LLP. Jeffrey serves on the board of directors of Infinity Pharmaceuticals, Inc. and ZappRx. He has been recognized three times in PharmaVOICE magazine as one of the 100 Most Inspiring Leaders in the Life Sciences.
Patrick J. Kennedy is a former member of the U.S. House of Representatives and the nation’s leading political voice on mental illness, addiction, and other brain diseases. During his 16-year career representing Rhode Island in Congress, he fought a national battle to end medical and societal discrimination against these illnesses, highlighted by his lead sponsorship of the Mental Health Parity and Addiction Equity Act of 2008. Patrick has since founded The Kennedy Forum, which leads a national dialogue on transforming mental health and addiction care delivery by uniting mental health advocates, business leaders, and government agencies, and co-founded One Mind, a global leader in open science collaboration in brain research. He is also the co-author of “A Common Struggle: A Personal Journey Through the Past and Future of Mental Illness and Addiction,” which details his personal struggles as well as his bold plan for the future of mental health care in America.
Dr. Dennis H. Langer has served as a Director of several biotechnology, specialty pharmaceutical, and diagnostic companies, and has been CEO and/or co-founder of several healthcare companies. Previously, Dennis served as a Managing Partner of Phoenix IP Ventures, a private equity/venture capital firm specializing in life sciences. Prior to that, he was President, North America, of Dr. Reddy’s Laboratories. Dennis has also held several leadership positions at GlaxoSmithKline and its predecessor, SmithKline Beecham, including Senior Vice President of Research and Development. He was President and CEO of Neose Technologies, Inc., and also held R&D and marketing positions at Eli Lilly, Abbott and Searle. He began his career as a Chief Resident at Yale University School of Medicine, and held clinical fellowships at Harvard Medical School and the National Institutes of Health. He serves as a Director of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc., Delcath Systems, Inc., and several private companies. He is a Clinical Professor in the Department of Psychiatry, Georgetown University School of Medicine.
Dr. Jerry Karabelas has held a number of senior executive positions in major pharmaceutical companies, including Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis AG, where he had full responsibility for Novartis Pharma and Ciba Vision, as well as strategic and operational leadership of R&D. He was also Executive Vice President of SmithKline Beecham with responsibility for U.S. and European operations, regulatory, and strategic marketing. Most recently, Jerry has chaired the boards of several biopharmaceutical companies, including Human Genome Sciences, Inc., Vanda Pharmaceuticals, Inc. and SkyePharma PLC. He currently chairs the boards of Inotek and Polyphor, AG and is a partner at Care Capital.
Dr. Seth Harrison is the managing partner of Apple Tree Partners and serves as Executive Chairman of Braeburn Pharmaceuticals. He has invested in life sciences since 1991. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. Previously, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. From 2002 – 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides.
David McIntyre brings 20 years of experience to Braeburn as a senior executive and corporate advisor with multinational and growth companies in a wide variety of industries, including life sciences and medical devices. With professional qualifications in finance and law, David has held senior financial, legal and operational roles. Since 2012, David has been a partner at Apple Tree Partners. Previously David was EVP, CFO of HeartWare International, Inc., and assumed the additional responsibilities of COO during HeartWare’s global commercialization phase. Prior to HeartWare, David practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multinational companies including Coal & Allied Limited, a publicly traded subsidiary of the Rio Tinto Group of companies.
Mike Derkacz leads Braeburn with passion and clarity, bringing 25 years of pharmaceutical industry experience to his role. Mike is an accomplished and highly successful leader, with deep expertise in building market-leading brands, conducting award-winning product launches, creating highly effective teams and developing sound commercial strategies to sustain market leadership. Prior to Braeburn, he was Senior Vice President and Head of Global CNS for Teva’s Global Specialty Medicines business. During his tenure at Teva, he led the launch of Copaxone 40mg, considered one of the most successful product introductions in the multiple sclerosis category and named pharma industry “Brand of the Year”. He joined Teva through the acquisition of Cephalon, where he served as Vice President, CNS Business unit. He spent the first 15 years of his career at GlaxoSmithKline — where he assumed positions of increasing leadership and commercial responsibility for major CNS and Cardiovascular brands.
Ted Buckley has been engaged in policy development and government relations for over 15 years. At Braeburn Ted heads up Government Affairs and Public Policy. Prior to joining Braeburn, Ted led Global Policy at Shire Pharmaceuticals after previously leading its US Government Relations and Public Policy team. While at Shire he engaged on issues ranging from regulations surrounding the exporting of controlled substances to laws enhancing incentives for the development of treatments for rare diseases. Previous experience includes serving as the chief economist at Bloomberg Government where he built and led a team of over 30 analysts that studied the impact of government actions on business. Also, as the economist for the Biotechnology Industry Organization, he researched, wrote on and developed policy proposals on topics including intellectual property, comparative effectiveness and biosimilars.
Susan Franks brings over 30 years of Regulatory and Project Management experience in the pharmaceutical industry from Wyeth, Premier Research Group, Cephalon and Teva Pharmaceuticals. At Braeburn, Susan heads the Regulatory Affairs function, driving regulatory strategies to optimize outcomes for Braeburn’s portfolio of drug products, as well as ensuring full adherence with FDA regulations for products in IND stage through NDA filing and beyond. Most recently, Susan led a large Global Regulatory organization for Teva’s Specialty portfolio of over 40 drug projects in global markets across multiple therapeutic areas, and previously focused in the areas of Pain and Infectious Disease. In the Pain/Opioid space, Susan led the successful registration of Exalgo® (hydromorphone extended release) and Vantrela® ER (hydrocodone), as well as managed FDA negotiations for a complex post-approval REMS program for Fentora® and Actiq (immediate release fentanyl products).